NZ514260A - A composition comprising Group C streptococcal phage associated lysin enzyme, and the use of this composition for preventing or treating streptoccocal infections - Google Patents
A composition comprising Group C streptococcal phage associated lysin enzyme, and the use of this composition for preventing or treating streptoccocal infectionsInfo
- Publication number
- NZ514260A NZ514260A NZ514260A NZ51426099A NZ514260A NZ 514260 A NZ514260 A NZ 514260A NZ 514260 A NZ514260 A NZ 514260A NZ 51426099 A NZ51426099 A NZ 51426099A NZ 514260 A NZ514260 A NZ 514260A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- group
- infections
- streptoccocal
- treating
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 4
- 108090000790 Enzymes Proteins 0.000 title abstract 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 title 1
- 101710126949 Lysin Proteins 0.000 title 1
- 239000004472 Lysine Substances 0.000 abstract 2
- 206010061372 Streptococcal infection Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ514260A NZ514260A (en) | 1999-02-25 | 1999-02-25 | A composition comprising Group C streptococcal phage associated lysin enzyme, and the use of this composition for preventing or treating streptoccocal infections |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1999/004063 WO2000050069A1 (en) | 1999-02-25 | 1999-02-25 | A means for the prophylactic and therapeutic treatment of streptococcal infections |
| US09/257,025 US6017528A (en) | 1997-10-31 | 1999-02-25 | Therapeutic treatment of group A streptococcal infections |
| NZ514260A NZ514260A (en) | 1999-02-25 | 1999-02-25 | A composition comprising Group C streptococcal phage associated lysin enzyme, and the use of this composition for preventing or treating streptoccocal infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ514260A true NZ514260A (en) | 2003-02-28 |
Family
ID=26795447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ514260A NZ514260A (en) | 1999-02-25 | 1999-02-25 | A composition comprising Group C streptococcal phage associated lysin enzyme, and the use of this composition for preventing or treating streptoccocal infections |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6017528A (enExample) |
| EP (1) | EP1162994A4 (enExample) |
| JP (1) | JP2002537350A (enExample) |
| KR (1) | KR20020000217A (enExample) |
| AU (1) | AU2876799A (enExample) |
| BR (1) | BR9917152A (enExample) |
| CA (1) | CA2366712A1 (enExample) |
| HK (1) | HK1047243A1 (enExample) |
| IN (1) | IN2001DE00791A (enExample) |
| MX (1) | MXPA01008701A (enExample) |
| NZ (1) | NZ514260A (enExample) |
| WO (1) | WO2000050069A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232576B2 (en) | 1997-10-31 | 2007-06-19 | New Horizons Diagnostics Corp | Throat lozenge for the treatment of Streptococcus Group A |
| US6277399B1 (en) | 1997-10-31 | 2001-08-21 | New Horizon Diagnostics Corporation | Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections |
| US6432444B1 (en) * | 1997-10-31 | 2002-08-13 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymes for treating dermatological infections |
| US6428784B1 (en) * | 1997-10-31 | 2002-08-06 | New Horizons Diagnostics Corp | Vaginal suppository for treating group B Streptococcus infection |
| US6335012B1 (en) | 1997-10-31 | 2002-01-01 | Vincent Fischetti | Use of bacterial phage associated lysing enzymes for treating bacterial infections of the mouth and teeth |
| US6399097B1 (en) | 1997-10-31 | 2002-06-04 | New Horizons Diagnostics Corporation | Composition for treatment of a bacterial infection of the digestive tract |
| US20030129147A1 (en) * | 1997-10-31 | 2003-07-10 | Vincent Fischetti | Use of bacterial phage associated lysing proteins for treating bacterial dental caries |
| US20020136712A1 (en) * | 1997-10-31 | 2002-09-26 | Fischetti Vincent | Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae |
| US20030129146A1 (en) * | 1997-10-31 | 2003-07-10 | Vincent Fischetti | The use of bacterial phage associated lysing proteins for treating bacterial dental caries |
| US6423299B1 (en) | 1997-10-31 | 2002-07-23 | Vincent Fischetti | Composition for treatment of a bacterial infection of an upper respiratory tract |
| US6056954A (en) * | 1997-10-31 | 2000-05-02 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses |
| US6399098B1 (en) | 1997-10-31 | 2002-06-04 | New Horizons Diagnostics Corp | Composition for treating dental caries caused by streptococcus mutans |
| US20030082110A1 (en) * | 1997-10-31 | 2003-05-01 | Vincent Fischetti | Use of bacterial phage associated lysing proteins for treating bacterial dental caries |
| US6248324B1 (en) | 1997-10-31 | 2001-06-19 | Vincent Fischetti | Bacterial phage associated lysing enzymes for treating dermatological infections |
| US6752988B1 (en) * | 2000-04-28 | 2004-06-22 | New Horizons Diagnostic Corp | Method of treating upper resiratory illnesses |
| US6406692B1 (en) * | 1997-10-31 | 2002-06-18 | New Horizons Diagnostics Corp | Composition for treatment of an ocular bacterial infection |
| US6326002B1 (en) | 1997-10-31 | 2001-12-04 | New Horizons Diagnostics Corporation | Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract |
| US7063837B2 (en) * | 1999-09-14 | 2006-06-20 | New Horizons Diagnostics Corp | Syrup composition containing phage associated lytic enzymes |
| US20020127215A1 (en) * | 1999-09-14 | 2002-09-12 | Lawrence Loomis | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| AU2001259205A1 (en) * | 2000-04-28 | 2001-11-12 | New Horizons Diagnostic Corporation | The use of bacterial phage associated lysing enzymes for treating various illnesses |
| AU2001263408A1 (en) | 2000-05-23 | 2001-12-03 | The Rockefeller University | C1 bacteriophage lytic system |
| US6395504B1 (en) | 2000-09-01 | 2002-05-28 | New Horizons Diagnostics Corp. | Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants |
| CA2427928A1 (en) * | 2000-11-02 | 2002-12-27 | New Horizons Diagnostics Corporation | The use of bacterial phage associated lytic enzymes to prevent food poisoning |
| US20040213765A1 (en) * | 2001-07-13 | 2004-10-28 | Vincent Fischetti | Use of bacterial phage associated lytic enzymes to prevent food poisoning |
| GB0118009D0 (en) * | 2001-07-24 | 2001-09-19 | Regma Biotechnologies Ltd | Novel preparation |
| US6759229B2 (en) * | 2001-12-18 | 2004-07-06 | President & Fellows Of Harvard College | Toxin-phage bacteriocide antibiotic and uses thereof |
| WO2004020451A1 (en) * | 2002-08-29 | 2004-03-11 | The Uab Research Foundation | Group b streptococcal phage lysin |
| US7569223B2 (en) * | 2004-03-22 | 2009-08-04 | The Rockefeller University | Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions |
| CA2833409A1 (en) | 2011-04-21 | 2012-10-26 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
| DK3369742T3 (da) | 2011-10-05 | 2020-10-19 | Univ Rockefeller | Dimere bakteriofaglysiner |
| JP6608697B2 (ja) | 2012-05-09 | 2019-11-20 | コントラフェクト コーポレイション | グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ |
| RU2646102C2 (ru) | 2012-05-09 | 2018-03-01 | Контрафект Корпорейшн | Предотвращение, разрушение и обработка биопленки лизином бактериофага |
| KR101723466B1 (ko) | 2015-10-08 | 2017-04-06 | 주식회사 인트론바이오테크놀로지 | 신규한 스트렙토코커스 이니에 박테리오파지 Ｓｔｒ-ＩＮＰ-1 및 이의 스트렙토코커스 이니에 균 증식 억제 용도 |
| DK3454888T3 (da) | 2016-05-12 | 2021-04-26 | Contrafect Corp | Bouillon-mikrofortyndingsfremgangsmåde til evaluering og bestemmelse af minimal inhibitorisk koncentration for antibakterielle polypeptider |
| WO2018011660A1 (en) | 2016-07-11 | 2018-01-18 | Philip Morris Products S.A. | Hydrophobic capsule |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3852424A (en) * | 1957-07-26 | 1974-12-03 | Ciba Geigy Corp | Purified ferrimycin and process for obtaining same |
| AU8108587A (en) * | 1986-10-08 | 1988-05-06 | David Bernstein | Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci |
| US5997862A (en) * | 1997-10-31 | 1999-12-07 | New Horizons Diagnostics Corporation | Therapeutic treatment of group A streptococcal infections |
-
1999
- 1999-02-25 HK HK02108859.1A patent/HK1047243A1/zh unknown
- 1999-02-25 CA CA002366712A patent/CA2366712A1/en not_active Abandoned
- 1999-02-25 JP JP2000600679A patent/JP2002537350A/ja active Pending
- 1999-02-25 MX MXPA01008701A patent/MXPA01008701A/es not_active Application Discontinuation
- 1999-02-25 BR BR9917152-0A patent/BR9917152A/pt not_active IP Right Cessation
- 1999-02-25 NZ NZ514260A patent/NZ514260A/xx unknown
- 1999-02-25 EP EP99909595A patent/EP1162994A4/en not_active Withdrawn
- 1999-02-25 US US09/257,025 patent/US6017528A/en not_active Expired - Fee Related
- 1999-02-25 WO PCT/US1999/004063 patent/WO2000050069A1/en not_active Ceased
- 1999-02-25 KR KR1020017010898A patent/KR20020000217A/ko not_active Ceased
- 1999-02-25 AU AU28767/99A patent/AU2876799A/en not_active Abandoned
- 1999-02-25 IN IN791DE2001 patent/IN2001DE00791A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002537350A (ja) | 2002-11-05 |
| HK1047243A1 (zh) | 2003-02-14 |
| CA2366712A1 (en) | 2000-08-31 |
| BR9917152A (pt) | 2002-11-26 |
| WO2000050069A1 (en) | 2000-08-31 |
| IN2001DE00791A (enExample) | 2007-05-25 |
| US6017528A (en) | 2000-01-25 |
| MXPA01008701A (es) | 2003-06-24 |
| EP1162994A4 (en) | 2004-12-29 |
| KR20020000217A (ko) | 2002-01-05 |
| EP1162994A1 (en) | 2001-12-19 |
| AU2876799A (en) | 2000-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ514260A (en) | A composition comprising Group C streptococcal phage associated lysin enzyme, and the use of this composition for preventing or treating streptoccocal infections | |
| MXPA02002895A (es) | Tratamiento topico de infecciones por estreptococcus. | |
| Smith et al. | Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations | |
| HK1047888A1 (zh) | 適用於不同的疾病預防及治療性療程的細菌性噬體溶素酶用途 | |
| GEP20053429B (en) | 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents | |
| IL171607A (en) | Use of botulinum toxin for the treatment of sinusitis-induced headaches | |
| IL195723A (en) | Use of p53 inhibitors for the preparation of medicament | |
| NZ552047A (en) | Method of treatment of endobronchial infections | |
| SE9702860L (sv) | Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod | |
| PT1161248E (pt) | Composição farmacêutica que contém uma fonte de nitrato e um agente acidificante destinada ao tratamento de feridas abertas e queimaduras | |
| AU8187901A (en) | Medicinal product package for eradication therapy | |
| GEP20002297B (en) | Alpha-Substituted Pyrimidine-Thioalhyl and Alkyl-Ether Compounds, Method for Treatment of Individual Infected with the Immunodeficiency Virus | |
| MY164077A (en) | Compositions and uses of et743 for treating cancer | |
| AU1865100A (en) | Hyaluronate lyase used for promoting penetration in topical agents | |
| HU229458B1 (en) | Pharmaceutical compositions containing zolmitriptan | |
| MY128739A (en) | Compositions and methods for treating bacterial infections | |
| DE60034879D1 (en) | Lantibiotikum | |
| DE69914911D1 (de) | Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen | |
| WO2001082945A3 (en) | The use of bacterial phage associated lysing enzymes for treating various illnesses | |
| ES2136206T3 (es) | Composicion antibacteriana que contiene alfalactalbumina multimerica. | |
| SE9601395D0 (sv) | New therapeutic treatment 1 | |
| NZ502861A (en) | Method of treating livestock bacterial respiratory or enteric infections using 9a-azalides | |
| ATE457730T1 (de) | Verabreichung von produkten des 5-lipoxygenase synthesewegs zur behandlung von mikrobiellen infektionen | |
| BR0115364A (pt) | Tratamento de disfunção sexual | |
| DE59808313D1 (de) | Verwendung von wirkstoffkombinationen aus antibiotika und terpenhaltigen pflanzenextrakten in der tiermedizin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed |